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An effective vaccine is a priority for malaria control and elimination. The leading candi-
date in the Plasmodium falciparum blood stage is PfRh5. PfRh5 assembles into trimeric
complex with PfRipr and PfCyRPA in the parasite, and this complex is essential for
erythrocyte invasion. In this study, we show that antibodies specific for PfRh5 and
PfCyRPA prevent trimeric complex formation.We identify the EGF‐7 domain on PfRipr
as a neutralising epitope and demonstrate that antibodies against this region act
downstream of complex formation to prevent merozoite invasion. Antibodies against
the C‐terminal region of PfRipr were more inhibitory than those against either PfRh5
or PfCyRPA alone, and a combination of antibodies against PfCyRPA and PfRipr acted
synergistically to reduce invasion. This study supports prioritisation of PfRipr for
development as part of a next‐generation antimalarial vaccine.1 | INTRODUCTION
Over half the world's population remains at risk from malaria, with
control efforts stalling and even being reversed in some of the highest
burden countries (WHO, 2016). The development of an effective
vaccine is a strategic priority in the global elimination of this disease
(Moorthy, Newman, & Okwo‐Bele, 2013). Plasmodium falciparum, the
causative agent of the most severe form of malaria, has a complex life
cycle and is transmitted to humans by Anopheles mosquitoes.- - - - - - - - - - - - - - - - - - - - - - - - - -
Creative Commons Attribution Li
ed by John Wiley & Sons LtdSporozoites injected into the skin infect hepatocytes in the liver in a
clinically silent pre‐erythrocytic phase of development. This phase is
followed by a release of hepatic merozoites into the blood stream.
These invade erythrocytes and perpetuate the pathogenic asexual
blood stage causing malaria.
The complexity of its lifecycle together with high levels of sequence
diversity in some of the early vaccine candidates (Conway, 2015) has
challenged vaccine development. The only candidate to make it to
Phase III clinical trials is the RTS,S/AS01 vaccine that targets the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 of 15 HEALER ET AL.circumsporozoite antigen present on the pre‐erythrocytic stage of
P. falciparum (Rts et al., 2012). This vaccine provides only moderately
protective efficacy with a duration of 2 years or less in the target
population of infants and children under 5 years of age (Greenwood &
Doumbo, 2016). Strategies are being designed to develop a more
effective vaccine. One approach is to include multiple antigens from
different lifecycle stages, with a focus on those known to be essential
for parasite growth and for which antibodies block development and
onward transmission. A leading candidate antigen is P. falciparum
reticulocyte binding protein homologue 5 (PfRh5; Payne et al., 2017).
PfRh5 is an essential protein for merozoite invasion that binds to
basigin, its receptor on the surface of the erythrocyte membrane (Baum
et al., 2009; Crosnier et al., 2011). The structure of PfRh5, both alone
and in complexwith basigin, has been determined by X‐ray crystallogra-
phy (Chen et al., 2014;Wright et al., 2014). In the parasite, PfRh5 forms
a trimeric complex with the cysteine‐rich protective antigen (CyRPA)
and PfRh5‐interacting protein (PfRipr) during merozoite invasion (Chen
et al., 2011; Reddy et al., 2015; Volz et al., 2016). The structure of
CyRPA has also been solved both by itself and in complex with invasion
inhibitory monoclonal antibodies (mAbs), revealing a six‐bladed
β‐propeller fold (Chen et al., 2017; Favuzza et al., 2017). The crystal
structure of PfRipr in isolation has not been solved; however, the struc-
ture of the PfRh5/CyRPA/PfRipr complex has recently been deter-
mined by cryo‐electron microscopy (Wong et al., 2019). The trimer
forms an extended structure with CyRPA at its centre binding through
opposing faces to PfRipr and PfRh5. Formation of this complex medi-
ates its efficient binding via PfRh5 to basigin, and this initiates insertion
of PfRh5 and PfRipr into the erythrocyte membrane, a pivotal step in
the function of the PfRh5/CyRPA/PfRipr complex (Wong et al., 2019).
Both CyRPA and PfRipr are also essential for merozoite invasion,
functioning at the same stage in this process as PfRh5 (Volz et al.,
2016). Both proteins are housed within merozoites in micronemes
(Chen et al., 2011; Volz et al., 2016), subcellular apically located organ-
elles containing mutiple invasion‐related proteins. Upon erythrocyte
contact and via a signalling mechanism that has yet to be fully under-
stood, micronemes release their contents, allowing the PfRh5/CyRPA/
PfRipr complex to form at the junction between the apical end of the
invading merozoite and the erythrocyte membrane (Volz et al., 2016).
The rationale for developing an invasion‐blocking vaccine that tar-
gets members of this protein complex comes from studies of mouse,
rabbit, and human and non‐human primate responses. Antibodies to
recombinant PfRh5 and basigin, as well as soluble basigin itself, block
the function of PfRh5 consequently inhibiting merozoite invasion
(Bustamante et al., 2013; Crosnier et al., 2011; Douglas et al., 2011).
Rabbit and mouse antibodies raised to recombinant CyRPA and PfRipr
also inhibit the function of these proteins and block merozoite invasion
(Chen et al., 2011, 2017; Douglas et al., 2015; Favuzza et al., 2017;
Reddy et al., 2014). Furthermore, vaccination of Aotus monkeys with
PfRh5 protected individuals against challenge with a heterologous
strain of P. falciparum (Douglas et al., 2015). PfRh5 and PfRipr antibodies
frommalaria‐exposed individuals in various endemic regions are associ-
ated with naturally acquired immunity to malaria (Chiu et al., 2014;
Richards et al., 2013; Tran et al., 2014) and inhibit parasite growth (Patelet al., 2013; Tran et al., 2014). Antibody responses to PfRh5, elicited in
nonexposed volunteers in a Phase 1a human clinical trial, likewise block
merozoite invasion in vitro (Payne et al., 2017). Monoclonal antibodies
to CyRPA provide protection against P. falciparumwhen passively trans-
ferred into a NOD/SCID IL2Rγ(null) mouse model engrafted with
human erythrocytes (Dreyer et al., 2012).
A PfRh5‐based vaccine is leading the clinical development path-
way (Hjerrild et al., 2016; Jin et al., 2018; Payne et al., 2017),
whereas CyRPA is also in development for testing in Phase 1 clinical
trials. But the third member of this essential complex, PfRipr, has not
received the same attention. This study was primarily designed to
address whether PfRipr warrants further preclinical development as
a potential blood‐stage malaria vaccine, either alone or in combina-
tion with PfRh5 and/or CyRPA. To understand the molecular basis
for antibody‐mediated growth inhibition, mAbs against PfRipr,
PfRh5, and CyRPA were tested for parasite growth inhibition and
for their effect on the assembly of the PfRh5/CyRPA/PfRipr com-
plex (Chen et al., 2017; Douglas et al., 2014). Furthermore, we
examined naturally acquired immunity to the PfRh5/CyRPA/PfRipr
complex and its components and show that individuals in the study
population with higher levels of antibodies to Ripr and Rh5 but not
CyRPA were protected from clinical malaria.2 | RESULTS
2.1 | Recombinant PfRipr forms a tripartite complex
with CyRPA and PfRh5
PfRipr is a 120‐kDa protein with 87 cysteine residues. It consists of two
regions that are separated by proteolytic cleavage both endogenously
and in the recombinant expression system. The N‐terminal region
contains two EGF‐like domains, whereas the C‐terminal region contains
eight EGF‐like domains (Figure 1a; Chen et al., 2011). In order to analyse
the function and immunogenicity of PfRipr, the full‐length mature
protein (residues 20–1086 of the translated protein product) was
expressed in Drosophila S2 cells (Fl‐Ripr) and purified from culture
supernatant by affinity and size‐exclusion chromatography (SEC;
Figure 1b). Additionally, specific domains of the PfRipr protein were
expressed in either baculovirus‐infected Sf21 cells (Ct‐Ripr, residues
608–1086), Escherichia coli (EGF6‐8, residues 791–900), or Pichia
pastoris (EGF7‐10, residues 816–961; EGF5‐7, 717–860; and EGF1‐2,
263–354; Figure 1a). Each of the purified proteins ran predominantly
as a single band on SDS‐PAGE gels (Figure 1c).
To assess whether purified recombinant Fl‐Ripr was functional and
capable of forming a complexwith PfRh5 (Chen et al., 2011) and CyRPA
(Chen et al., 2017), the proteins were incubated together and analysed
by SEC (Figure 1d; Wong et al., 2019). This showed that the three pro-
teins were present in approximately equimolar ratios in all fractions
derived from themajor peak, demonstrating the formation of a tripartite
complex. This confirmed that the recombinant Fl‐Ripr was functional
and conformationally intact by its ability to form a stable tripartite com-
plex with PfRh5 and CyRPA (Wong et al., 2019).
FIGURE 1 Domain structure of PfRipr and
expression of recombinant proteins. (a)
Domain structure of PfRipr showing the
location of the EGF‐like domains (blue) and a
protease processing site (scissors). Also shown
are the boundaries of the recombinant proteins
expressed to represent different domains of
the PfRipr protein with residue range shown in
brackets. (b) Expression and purification of Fl‐
Ripr (amino acids 20–1086) from S2
Drosophila cells. Shown in the left panel is a
SDS‐PAGE gel stained with Coomassie blue
with molecular weight markers. Supern, culture
supernatant; Input, concentrated supernatant
loaded for affinity purification; Ft, flow through
from affinity column; Elution, fractions eluted
from affinity column. (c) Recombinant domains
of PfRipr (as depicted in a) purified and stained
with Coomassie blue. (d) SEC analysis of the
PfRh5/CyRPA/PfRipr complex detected using
Coomassie blue staining (lower panel)
HEALER ET AL. 3 of 152.2 | Monoclonal antibodies that bind PfRipr inhibit
P. falciparum growth
Polyclonal antibodies to short regions of PfRipr were shown
previously to inhibit P. falciparum growth (Chen et al., 2011). In order
to understand the molecular mechanism involved, we derived mAbs
to Ct‐Ripr (Figure 1a). Five mAbs (1C4, 3C3, 4A8, 5G6, and 1G12)
were analysed by immunoblotting to determine their reactivity to
Fl‐Ripr (Figure 2a). All mAbs bound to Fl‐Ripr under nonreducing
conditions. Reactivity, however, was significantly decreased underreducing conditions and reduced Fl‐Ripr proved undetectable by
1G12 (Figure 2a).
We next used growth‐inhibition assays (GIA) to determine whether
these mAbs had an effect on the ability of P. falciparum to invade and
grow in human erythrocytes (Figure 2b). Although 1C4, 3C3, and 4A8
did not have any significant effect on parasite growth, 5G6 and 1G12
showed significant inhibition, with IC50 values of approximately 0.8
and 0.35 mg/ml, respectively. The level of inhibition with these mAbs
is comparable to that reported in published studies with mAbs raised
against Rh5 (Douglas et al., 2014).
FIGURE 2 Identification of invasion neutralising monoclonal antibodies and mapping of epitopes on PfRipr. (a) Immunoblots of FL‐Ripr under
reduced (R) and nonreduced (NR) conditions after SDS‐PAGE using monoclonal antibodies raised to CT‐Ripr. Monoclonal antibodies used were
1C4, 3C3, 4A8, 5G6, and 1G12. (b) Growth inhibition assays (GIA) of the anti‐Ripr monoclonal antibodies using 3D7 Plasmodium falciparum
parasites. (c) Immunoblots of PfRipr recombinant protein domains to map the monoclonal antibody epitopes (1C4, 3C3, 4A8, 5G6, and 1G12). The
final panel was screened using rabbit anti‐Fl‐Ripr polyclonal antibodies. (d) Domain structure of PfRipr and mapping of the spatial location of
monoclonal antibody epitopes
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were tested by immunoblot against specific recombinant domains of
the protein under nonreducing conditions (Figure 2c). The noninhibitory
mAbs 1C4, 3C3, and 4A8 reacted with only Ct‐Ripr and did not bind to
EGF 6‐8, EGF 1‐2, EGF 5‐7, or EGF 7‐10. Therefore, 1C4, 3C3, and 4A8
most likely bind to epitopes outside EGF 4‐10 but within the Ct‐Ripr
domain (Figure 2d). The neutralising mAbs 5G6 and 1G12 reacted with
nonreduced Fl‐Ripr, Ct‐Ripr, EGF 6‐8, EGF 7‐10, and EGF 5‐7 but not to
EGF 1‐2. This finding was therefore consistent with the epitopes for
both 5G6 and 1G12 being contained within domain EGF 7 of PfRipr(Figure 2d, red bar). The data were consistent with 1G12 and 5G6 bind-
ing to the same or overlapping epitopes. Similarly, 1C4, 3C3, and 4A8
may also bind to different but overlapping epitopes within the the
C‐terminal region of PfRipr (Figure 2d, indicated as grey bars).
2.3 | Kinetic properties of monoclonal antibodies
that bind to PfRipr and CyRPA
In order to determine if the anti‐PfRipr monoclonal antibodies bound
to overlapping epitopes, we used surface plasmon resonance (SPR)
HEALER ET AL. 5 of 15to measure their kinetic properties and competition studies to
understand if they bound to spatially related areas of the Fl‐Ripr
protein. Amine coupling mAb 1C4 to the chip did not provide a
response in SPR experiments, likely due to the presence of a lysine
in one of the complementary‐determining regions interfering with
the SPR sensor surface blocking interactions with the antigen, and
kinetic data were not obtained for this antibody. The equilibrium
dissociation constants (KD) measured for 1G12, 5G6, 4A8, and 3C3
were between 4 × 10−11 and 2.4 × 10−10M showing these mAbs
have a high affinity for their specific epitope (Figure S1A). However,
the neutralising antibodies 1G12 and 5G6 have a threefold to sixfold
tighter affinity than 4A8 and 3C3 (nonneutralising) driven by a
tenfold to 20‐fold decrease in off rate. The comparable on and off
rates for the kinetic dissociation (kd) and association (ka) constants
for 4A8 and 3C3 are suggestive that they may bind a common
epitope. The nonneutralising mAbs had a significantly faster off rate
compared with the neutralising antibodies.
To determine which PfRipr mAbs bound to overlapping epitopes,
competition assays were performed using SPR. MAbs 1G12 and
5G6 efficiently competed with each other and similarly 4A8, 3C3,
and 1C4 also showed competitive binding to Fl‐Ripr (Figure S2). In
contrast, 1G12 did not compete for binding to Fl‐Ripr with 4A8 or
3C3. Similar results were obtained for 5G6 (Figure S3). The competi-
tive binding of 1G12 and 5G6 for binding to Fl‐Ripr is consistent with
these mAbs binding to overlapping epitopes within the EGF 7 domain
of Fl‐Ripr. Similarly, the properties of 4A3, 3C3, and 1C4 suggest that
they bind to an overlapping epitope in a distinct region of the Ct‐Ripr
domain (Figure 2d).
For comparison with the anti‐PfRipr antibodies, the kinetic
parameters of mAbs raised previously to CyRPA, which we had
shown to block growth of P. falciparum parasites (Chen et al.,
2017), were measured (Figure S1B). The anti‐CyRPA mAbs 8A7,
5B12, and 3D1 inhibit P. falciparum growth as efficiently as the
anti‐PfRipr monoclonal antibody 5G6 (Chen et al., 2017). The KD
values for the CyRPA mAbs ranged from 5.7 × 10−10 to
2.7 × 10−9M, which was weaker than those measured for the PfRipr
neutralising antibodies. The ka values for 8A7, 5B12, and 3D1 were
similar, whereas the kd values varied substantially, from 9.1
(±3.7) × 10−5 s−1 to 1.28 (±0.37) × 10−4 s−1.
We additionally used SPR to determine if the CyRPA mAbs bind
overlapping epitopes. 3D1, 5B12, and 8A7 all showed competitive
inhibition of binding, confirming that they bound to spatially similar
epitopes on the CyRPA protein (Figures S1C and S4). As a control,
we showed that the anti‐PfRipr antibody 3C3 shows no competitive
inhibition against 8A7, 5B12, and 3D1 for binding to CyRPA. These
competition SPR data are summarised in Table S1.2.4 | Neutralising antibodies can block formation of
the PfRh5/CyRPA/PfRipr complex
To understand the molecular mechanism of inhibition of merozoite
invasion by the neutralising monoclonal antibodies to PfRipr, PfRh5,and CyRPA, we determined if they could block formation of the
PfRh5/PfRipr/CyRPA tripartite complex (Figure 3). The proteins were
pre‐incubated together in the presence of the different mAbs and the
complexes analysed using SEC (Figure 3). MAb 2AC7 binds to PfRh5
and has previously been shown to inhibit parasite growth in vitro,
and its epitope was located to a position on PfRh5 distinct from the
basigin binding region (Douglas et al., 2014). In SEC, assays that detect
complex formation 2AC7 block the ability of PfRh5 to bind directly to
the CyRPA/PfRipr bipartite complex (Figure 3a). The bipartite CyRPA
and PfRipr complex was able to form, and a PfRh5/2AC7 antibody
complex was also observed. Therefore, the 2AC7 anti‐PfRh5 monoclo-
nal inhibits merozoite invasion through interference with formation of
the PfRh5/CyRPA/PfRipr complex whereas other anti‐PfRh5 antibod-
ies can block ligand‐receptor binding.
As a control, we tested the ability of the noninhibitory anti‐Ripr
monoclonal antibody 1C4 and found that it did not block formation
of the ternary PfRh5/CyRPA/PfRipr complex but instead bound to
PfRipr forming a quaternary complex (Figure S5). Similarly, the anti‐
PfRipr neutralising antibodies 5G6 and 1G12 did not block formation
of the PfRh5/CyRPA/PfRipr complex but formed quaternary com-
plexes (Figures 3b and S5). Therefore, the neutralising antibodies
5G6 and 1G12 seem not to inhibit merozoite invasion through
blocking formation of the PfRh5/CyRPA/PfRipr complex but likely
interfere with the downstream function of this tripartite complex.
We had previously shown that mAb 8A7 binds CyRPA and blocks
interaction with PfRh5 (Chen et al., 2017). This was confirmed here
because when we tested the ability of this antibody to interfere with
formation of the PfRh5/CyRPA/PfRipr complex using SEC (Figure 3c),
both the ternary PfRipr/CyRPA/8A7 antibody complex and free PfRh5
were detected. In contrast, the growth‐inhibitory CyRPA mAbs 3D1
(Figure 3d) and 5B12 (Figure S5) formed quaternary PfRh5/CyRPA/
PfRipr/3D1 and PfRh5/CyRPA/PfRipr/5B12 complexes. That only
8A7 (and not 3D1 or 5B12) blocked participation of CyRPA in the
PfRh5/CyRPA/PfRipr complex must be reconciled with SPR results
showing that 8A7, 3D1, and 5B12 compete for the same or similar epi-
topes on CyRPA. The slower disassociation rate of 8A7 (9.1 × 10−5 s−1)
compared with 3D1 (1.28 × 10−4 s−1) and 5B12 (5.9 × 10−4 s−1) may be
crucial for its ability to block PfRh5 binding. Taken together, these
results show that neutralising antibodies block merozoite invasion
through inhibition of formation of the PfRh5/CyRPA/PfRipr complex
as well as through other mechanisms.2.5 | Antibodies to PfRh5, CyRPA, PfRipr, and the
PfRh5/CyRPA/PfRipr complex inhibit P. falciparum
growth
Polyclonal antibodies to the individual antigens PfRipr, PfRh5, and
CyRPA were previously shown to inhibit merozoite invasion and con-
sequently growth of P. falciparum in vitro (Baum et al., 2009; Patel
et al., 2013; Reddy et al., 2014; Reddy et al., 2015; Weiss et al.,
2015; Williams et al., 2012). However, it is unknown if antibodies
raised to the PfRh5/CyRPA/PfRipr complex are more efficient than
FIGURE 3 Neutralising monoclonal antibodies against PfRh5, PfRipr, and CyRPA and effect on PfRh5/CyRPA/PfRipr complex formation. (a) SEC
analysis of inhibitory monoclonal antibody 2AC7 which binds to PfRh5 showing it blocks PfRh5/CyRPA/PfRipr complex formation. (b) SEC
analysis of inhibitory monoclonal antibody 5G6 which binds to PfRipr but does not block PfRh5/CyRPA/PfRipr complex formation. Proteins are
stained with Coomassie blue. SEC analysis for 1G12 and 1C4 are shown in Figure S5. (c) SEC analysis of inhibitory monoclonal antibody 8A7
which binds to CyRPA and blocksPfRh5/CyRPA/PfRipr complex formation. (d) SEC analysis of inhibitory monoclonal antibody 3D1 which binds to
CyRPA but does not block PfRh5/CyRPA/PfRipr complex formation. Proteins in all SDS‐PAGE gels are stained with Coomassie blue. SEC analysis
for 5B12 is shown in Figure S5. Traces shown above SEC gel profiles in all panels give elution volumes of molecular weight standards in kDa.
Models of mAb binding to antigens and their effect on complex formation are shown underneath respective SEC panels
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To test this, in vitro growth‐inhibition assays were performed with
the P. falciparum strains 3D7, W2mef, FCR3, and FVO (Figure 4a,b).
Rabbits were immunised with the individual antigen components or
equivalent amount of the assembled complex, where the components
were in a 1:1:1 molar ratio. Antibodies to Ct‐Ripr resulted in signifi-
cantly higher levels of growth inhibition for all P. falciparum strains
tested with approximately 94.3% and antibodies against Fl‐Ripr
resulted in 73.3% inhibition at 5 mg/ml (Figure 4a,b). In comparison,
antibodies to CyRPA and PfRh5 were less inhibitory when compared
across all four strains, at 64.4% and 46.8%, respectively. ConsistentFIGURE 4 Antibodies against PfRh5,
CyRPA, and PfRipr inhibit Plasmodium
falciparum growth. (a) Growth inhibition
assays using IgG rabbit antibodies raised to
equal concentrations of Ct‐Ripr, Fl‐Ripr,
CyRPA, PfRh5/CyRPA/PfRipr complex or
PfRh5 with P. falciparum strains 3D7, W2mef,
FCR3, and FVO. Plots are data from two
biological replicates with mean and SEM
shown. (b) Combined summary of GIA assays
at 5 mg/ml IgG for 3D7, W2mef, FCR3, and
FVO. (c) GIA assays using 3D7 parasites
where anti‐Fl‐Ripr, CyRPA, and PfRh5
antibodies have been added in combinations.
Total IgG concentration shown on x‐axis. (d)
GIA assays using 3D7 parasites where
polyclonal antibodies against Rh5, CyRPA and
PfRipr have been combined to a total IgG
concentration of 6 mg/ml. * Denotes
significantly different activity p < .05 (t test).
(e) Expected and actual level for inhibition of
parasite growth when CyRPA and PfRipr
monoclonal antibodies have been combined.
Monoclonal antibodies against Ripr (1G12 and
5G6) were combined with those against
CyRPA (5G6 and 5B12). Shown in black bars
is the expected level of inhibition derived by
adding the GIA activity of the individual mAbs
each at a concentration of 0.25 mg/ml. In grey
bars is the actual GIA activity of the combined
mAbs at a total concentration of 0.5 mg/ml
(0.25 mg/ml of each)with the absence of significant polymorphism in these antigens in
the P. falciparum population, antibodies to each of the individual
proteins and the complex showed no significant difference in GIA
against 3D7, W2mef, FCR3, or FVO. Antibodies raised to the
PfRipr/CyRPA/PfRipr complex showed the lowest level of inhibition
(Figure 4a), comparable with PfRh5 antibodies when compared across
the four strains (Figure 4b).
This result suggested that the epitopes of some neutralising
antibodies were buried in the PfRipr/CyRPA/PfRipr ternary complex
and that immunizing with individual proteins may be a preferable
option. To explore this possibility further, we tested the ability of
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P. falciparum growth (Figure 4c,d). A combination of antibodies to
Fl‐Ripr/CyRPA, PfRh5/Fl‐Ripr, and PfRh5/FL‐Ripr/CyRPA was all able
to inhibit P. falciparum growth to approximately 70% at 6 mg/ml. In
contrast, the combination of PfRh5/CyRPA antibodies was signifi-
cantly less efficient in their ability to block parasite growth (p = .01).
Taken together, these results show that antibodies raised to Fl‐Ripr
inhibited P. falciparum growth more effectively than those raised
against PfRh5 and CyRPA.
Comparative ELISA was performed to examine whether serum
titres of antibodies correlated with GIA activity. In these assays, sera
raised against the antigens in trimeric complex was tested alongside
sera raised against the individual antigens with the individual antigen
on the plate (Figure S6). This demonstrated that even when rabbits
were immunised with excess antigen (200 μg per dose), the resulting
antibody titres were always lower in the complex sera than when a
single immunising antigen was used. This was most striking in the case
of sera against CyRPA, where approximately 30‐fold lower titres were
seen for CyRPA in complex with Ripr and Rh5 compared with CyRPA
as a single immunogen. Titres against Rh5 were around tenfold lower
in the sera raised against the Rh5/CyRPA/Ripr complex whereas titres
against Ripr_FL in the complex were around threefold lower.
In further experiments, a combination of the neutralising monoclo-
nal antibodies against PfRipr and CyRPA was tested for their ability to
inhibit P. falciparum growth (Figure 4e). The mAbs 8A7 (anti‐CyRPA),
1G12 (anti‐PfRipr), and 5G6 (anti‐PfRipr) and their combinations
8A7/1G12, 8A7/5G6, and 1G12/5B12 were tested in GIA. Combina-
tions of mAbs (0.5 mg/ml total, or 0.25 mg/ml each) were assessed in
GIA. The percentage growth inhibition values were plotted alongside
an “expected” level of inhibition obtained by summing growth‐
inhibition percentages for the individual antibodies at 0.25 mg/ml
each (Figure 4e). In all cases, the combinations brought about much
greater levels of inhibition than the sum of the individual components,
suggesting a synergistic effect. Overall, these results suggest that anti-
bodies to PfRipr are more efficient at blocking P. falciparum growth
than antibodies to PfRh5 or CyRPA, but combinations of antibodies
to multiple components of the protein complex resulted in the highest
inhibition values.2.6 | Associations between antibody responses to
PfRh5, CyRPA, PfRipr, and the PfRh5/CyRPA/PfRipr
complex and protection from clinical malaria
We investigated the association between protection from reinfection
with P. falciparum malaria and antibody titres in response to PfRh5,
CyRPA, and PfRipr, as well as the complexes PfRh5/CyRPA,
CyRPA/PfRipr, and PfRh5/CyRPA/PfRipr. We used plasma samples
collected from a longitudinal cohort of 206 children living in a
malaria‐endemic area of Papua New Guinea (Figure 5). Antibody
titres were measured to the recombinant proteins alone or in binary
and ternary complexes. Antibody titres were heterogenous and, for
analysis, recipients were divided into terciles of low (L)‐, medium(M)‐, and high (H)‐level responders. The time‐to‐reinfection, and first
clinical episode and differences between high/medium and low
responders, was determined by Kaplan–Meier survival curves with
log rank test and Cox proportional hazards models (Figure 5a,b). A
Poisson regression model was used to analyse the differences of
clinical incidences between groups (Figure 5c). Statistical analysis of
the Kaplan–Meier survival curves revealed significant differences
between high‐/medium‐level responders and low‐level responders
to PfRh5 and PfRipr in time‐to‐reinfection and proportions of indi-
viduals remaining malaria‐free, with higher antibody levels associated
with less malaria (Figure 5a). High‐ and medium‐level antibody
responses to PfRh5 and PfRipr were associated with a significantly
lower risk of clinical episode compared with low‐level responses,
both in terms of time to first microscopy‐positive blood smears
(Figure 5a) and the time‐to‐first clinical episode (Figure 5b) and the
incidence of clinical episodes (Figure 5c). Conversely, no significant
differences were observed between groups in response to CyRPA;
and the CyRPA/PfRipr and PfRh5/CyRPA/PfRipr complexes gave
similar responses to those of PfRh5 and PfRipr antigens alone.
PfRipr showed stronger associations with protection than Rh5 and
adding Rh5 into a multivariate model including both antigens did
not significantly improve the associations with protection (data not
shown). This finding suggests that higher levels of naturally acquired
antibodies to PfRh5 and PfRipr are associated with protection
against clinical malaria following natural exposure to P. falciparum,
whereas even relatively high levels of naturally acquired antibodies
against CyRPA are not associated with similar protection.3 | DISCUSSION
The PfRh5/CyRPA/PfRipr complex is essential for invasion of merozo-
ites into human erythrocytes (Volz et al., 2016), and consequently
these proteins are potential candidates for inclusion in a vaccine
against malaria. PfRh5 and CyRPA are under preclinical investigation
as vaccine candidates, whereas a role for PfRipr remains unexplored
in this respect. The current study was undertaken to examine whether
the trimeric protein complex, or PfRipr alone, may be important
vaccine candidates that should be further pursued for preclinical
development.
A major impediment for developing PfRipr as a potential vaccine
component has been its complex, disulphide‐linked domain structure
and the inability to express a functional form of the full‐length
protein (Chen et al., 2011). Using a Drosophila cell expression
system, we have expressed and purified full‐length functional recom-
binant PfRipr that can form a trimeric complex with PfRh5 and
CyRPA. Previously, the same expression system was used to obtain
large quantities of functional PfRh5 for vaccine trials (Hjerrild
et al., 2016; Jin et al., 2018). Thus, it provides a potential means
to produce GMP‐quality PfRipr for testing its potential as a vaccine
against malaria in human clinical trials. It could also be a useful tool
for further biological studies.
FIGURE 5 Antibodies to PfRh5 and PfRipr are associated with protection from clinical malaria. (a) Time to first light microscopy positive
parasitemia with ≥5,000 parasites/μl in individuals with low (L), medium (M), or high (H) titers of antibody to PfRh5, PfRh5/CyRPA, PfRh5/
CyRPA/PfRipr, CyRPA, PfRipr, CyRPA/PfRipr at study enrolment, as determined with Kaplan–Meier survival analysis. (b) Hazard ratios were
determined to assess associations of antibody responses with time to first clinical episode and (c) incidence rate ratios were determined to assess
associations between antibody responses and incidence of clinical episodes. Age‐adjusted ratios with 95% confidence interval are shown. Clinical
episode was defined by the presence of fever plus light microscopy positive parasitemia with ≥5,000 parasites/μl. *p ≤ .05, **p ≤ .01
HEALER ET AL. 9 of 15The PfRh5/CyRPA/PfRipr complex as well as PfRh5, PfRipr, and
CyRPAalonewas used to raise antibodies thatwere tested for their abil-
ities to inhibit growth of four independent strains of P. falciparum. Of the
polyclonal antibodies tested here by GIA, those to the C‐terminal por-
tion of PfRipr were the most inhibitory, despite having very similar
ELISA reactivity (and thus antibody titre) against Ripr_FL to antibodiesraised against this antigen. Unfortunately, this antigen was not suitable
for further vaccine development due to its propensity to form highly
aggregated multimers (Healer & Cowman, unpublished data). Antibod-
ies raised against full‐length Ripr performed second best in GIA,
followed closely by those raised against PfCyRPA. We observed that
antibodies to PfRh5 and the PfRh5/CyRPA/PfRipr complex were less
10 of 15 HEALER ET AL.inhibitory in these assays. In combinatorial assays using antibodies
against Fl‐Ripr, CyRPA, and Rh5, all the more potent combinations
included anti‐Fl‐Ripr antibodies. The finding that combinations of mAbs
against PfRipr and CyRPA acted synergistically to block P. falciparum
invasion and growth supports further study to determine whether
inclusion of at least two of the antigens present in the invasion complex
in an antimalarial vaccine provides better levels of protection than a
single antigen.
These results contrasted with the somewhat higher levels of GIA
seen in other PfRh5 vaccination studies in rabbits (Bustamante et al.,
2013; Douglas et al., 2011). This may arise from the fact that the
protein used in this study, despite its ability to bind to basigin (Chen
et al., 2014) and form a ternary complex with CyRPA and Ripr, was
produced as a truncated protein, lacking the 15 kDa N‐terminal
portion. Note that the N‐terminal region of PfRh5 is cleaved from
the protein and not required for basigin binding although antibodies
against this specific domain were inhibitory in GIA assays (Galaway
et al., 2017). Furthermore, it is difficult to directly compare GIA
results from different studies using different antibody concentrations
and different assay measurements. Note that the N‐terminal region
of PfRh5 is cleaved from the protein and not required for basigin
binding although antibodies against this specific domain were
inhibitory in GIA assays (Galaway et al., 2017). A detailed
comparison of the inhibitory effects of each the monoclonal
antibodies against Rh5, CyRPA, and Ripr would identify protective
epitopes on these proteins and could be used to further inform
vaccine design.
A previous study has shown the protein P113 serves as the anchor
for this complex on the merozoite surface for binding to basigin by
binding to the 15 kDa N‐terminus of PfRh5 (Galaway et al., 2017).
Other studies have shown that P113 associates with the PTEX
translocon in the parasitophorous vacuole (Elsworth et al., 2016) and
its orthologue in P. berghei does not function in merozoite invasion
(Offeddu, Rauch, Silvie, & Matuschewski, 2014). Additionally,
immuno‐precipitation of PfRh5 and the PfRh5/CyRPA/PfRipr complex
in P. falciparum has not identified any interaction of P113 (Volz et al.,
2016). Further data are required to confirm if P113 plays a role in
the function of the PfRh5/CyRPA/PfRipr complex in merozoite inva-
sion and the function of the N‐terminal 15 kDa region of PfRh5 and
its potential importance in immunity.
Our results show that the PfRh5/CyRPA/PfRipr complex was not
a better immunogen in terms of producing more‐potent parasite
growth‐inhibitory antibodies compared with PfRh5, PfRipr, or CyRPA
alone. The comparative ELISA demonstrated that CyRPA, Rh5, and
Ripr were less immunogenic when presented in the 1:1:1 trimeric
complex. This difference was most striking for CyRPA, which, after
adjusting for relative difference in antigen dose between single and
complex immunisation, resulted in approximately 7.5‐fold lower anti-
body titres when presented in the trimeric complex compared with
immunisation as a single immunogen. This finding confirms predic-
tions from the structural model that the inhibitory epitopes on
CyRPA are masked by the binding faces of Ripr and Rh5. This was
also the case for Rh5 and Ripr but to a lesser degree, perhapssuggesting that there was a level of immune interference between
the three antigens when immunised as a complex, although there
is a level of inter‐rabbit variation in responsiveness against any anti-
gen so it is difficult to make conclusive statements without further
studies to this effect (Elias et al., 2013).
The relatively lower GIA activity seen with the complex IgG also
suggests that neoantigens arising from the molecular interactions
within the complex are not as important as those accessible to
antibody in the individual proteins when it comes to induction of
growth‐inhibitory antibodies (in rabbits). Some of the epitopes of
neutralising antibodies present in individual antigens are masked or
presented differently in the complex.
These results demonstrate that blocking the PfRh5/CyRPA inter-
action inhibits complex assembly, and this is an important mechanism
by which antibodies inhibit merozoite invasion of erythrocytes. In con-
trast, parasite‐neutralising anti‐Ripr mAbs did not interfere with
PfRh5/CyRPA/PfRipr complex formation, suggesting they inhibit mer-
ozoite invasion through a different mechanism. The inhibitory epitope
of these anti‐PfRipr mAbs is within the EGF 7 domain, suggesting that
this region plays an important function other than complex associa-
tion. Neutralising antibodies to EGF‐7 may act to block insertion of
PfRipr into the erythrocyte membrane (Wong et al., 2019). Neverthe-
less, it is clear that an antibody response to epitopes on the EGF 7
domain of this protein can play an important role in blocking merozo-
ite invasion of P. falciparum.
The anti‐CyRPA mAb 8A7 blocks assembly of PfRh5 into the
complex whereas 3D1 and 5B12 do not, despite them all binding
to common epitopes. Parallel studies of the CyRPA crystal structure
determined that monoclonal antibodies 8A7 and C12 in fact bind to
proximal but not identical regions of CyRPA, which may explain their
differential abilities to block the Rh5‐CyRPA interaction (Chen et al.,
2017; Favuzza et al., 2017). Based on cryo‐EM and crosslinking
studies (Wong et al., 2019), the C‐terminal tail of Rh5 interacts with
blade 1 beta sheet of CyRPA. The CyRPA‐8A7 crystal structure
showed that 8A7 binds to blade 1‐2 of CyRPA therefore explaining
the ability of 8A7 to inhibit PfRh5‐CyRPA interaction, whereas the
CyRPA‐C12 crystal structure showed that C12 binds to blade 2‐3
of CyRPA.
The affinity of binding for the three CyRPA mAbs was very similar,
but 8A7 had a much slower dissociation rate compared with 3D1 and
5B12. However, all the three mAbs showed similar levels of inhibition
in GIA, suggesting that differences in the kinetic properties of these
antibodies were not a factor in binding to and inhibiting parasite inva-
sion. Although 8A7 may interfere with merozoite invasion by blocking
of PfRh5 binding to CyRPA, both 3D1 and 5B12 must act via a distinct
mechanism such as steric hindrance that interferes with subsequent
functions of the PfRh5/CyRPA/PfRipr complex.
Our analysis confirms previous studies showing that naturally
acquired antibodies to PfRh5 and PfRipr are significantly associated
with protection from malaria in longitudinal cohort studies of chil-
dren exposed to P. falciparum (Chiu et al., 2014; Richards et al.,
2013; Tran et al., 2014; Weaver et al., 2016). In contrast, no associ-
ation with protection was found with antibodies to CyRPA nor to
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form a complex, except when CyRPA is present (Wong et al.,
2019), so this combination was not included in these assays.
Antibodies against the CyRPA/Ripr binary complex appeared to
show no additional benefit in terms of relative risk of malaria
compared with responses against PfRh5 or PfRipr alone.
Antibodies to the ternary complex were also significantly associ-
ated with protection. The significant protection that appears to be
associated with higher levels of antibodies to the complex may simply
reflect the importance of antibodies to Rh5 and Ripr, as it is impossible
to determine in these assays what epitopes are relevant to the protec-
tive response. The significant association seen with antibodies to the
binary CyRPA/Ripr complex suggests this to be the case. However,
unequivocal proof that antibodies against Ripr and Rh5 are responsi-
ble for clinical protection from malaria would require testing in human
clinical trials.
A possible explanation for the apparent discordancy between the
observed lack of significant association observed between antibodies
to CyRPA acquired by natural exposure to P. falciparum and the results
presented here with vaccination‐induced antibodies blocking invasion
of parasites in vitro is that antibody titres against neutralising epitopes
in a natural infection may not reach the level required for a functional
protective response. Related to this may be that in P. falciparum
infections, the antigens are present predominantly in a ternary com-
plex and the key neutralising epitopes on CyRPA are hidden at the
interface with Rh5. It is important to note that vaccination with
CyRPA alone induced antibodies with growth‐inhibitory activity, and
therefore, further studies to examine an immunisation approach that
includes uncomplexed CyRPA in combination with other antigens
would be of interest.
The lack of significant association between antibodies against
CyRPA and protection from P. falciparum malaria is consistent with
a previous study identifying potential combinatorial antibody
associations for P. falciparum vaccine development, in that antibodies
to CyRPA produced as a full‐length protein in HEK293 cells showed
no association with protective immunity in Malian children, whereas
IgG raised against the recombinant protein was significantly
inhibitory against parasite growth in GIA assays (Bustamante et al.,
2017). The authors concluded that PfCyRPA is poorly immunogenic
in humans. In contrast to this, antibodies against PvCyRPA were a
key component in combinations of antibodies associated with
protective immunity against P. vivax malaria (Franca et al., 2017).
Because these two antigens are closely related, this finding raises
interesting questions about their relative immunogenicity in humans
with exposure to the different species of Plasmodium. Ripr
orthologues are found in other Plasmodium species including P. vivax,
so a better understanding of the potential interactions of these
proteins could provide deeper insights into their biological role
across the genus and their importance as vaccine candidates.
These results support inclusion of PfRipr in future malaria vaccine
development programs and suggest that either alone or coimmunized
with an effective PfRh5 or CyRPA antigen, Ripr could provide superior
protection against blood stage malaria.4 | EXPERIMENTAL PROCEDURES
4.1 | Expression and purification of recombinant
proteins
Full‐length PfRipr (amino acids 20–1086) was expressed in Drosophila
S2 cells (ExpreS2ion Biotechnologies) and purified using Strep‐
Tactin®XT and size exclusion chromatography (Hjerrild et al., 2016).
A synthetic gene of Ct‐Ripr (encoding amino acids 604–1086;
Geneart) was cloned into the insect cell vector pgpHFT (Xu et al.,
2010). pgpHFT‐ct‐Ripr was cotransfected with FlashBAC (Oxford
Expression Technologies) in Sf21 cells. The seed virus was amplified
to obtain high titre virus stocks which were used to induce protein
expression in Sf21 cells. The FLAG‐tagged protein was purified by
affinity capture on anti‐FLAG M2 agarose resin (Sigma Aldrich). Bound
proteins were eluted with FLAG peptide and further purified using size
exclusion chromatography.
The EGF1‐2 synthetic gene (encoding amino acids 263–354) was
cloned into the pET45b + plasmid with a hexa‐His tag and enteroki-
nase cleavage site at the N‐terminus and transformed into E. coli cells
for protein expression. The recombinant protein was purified from
inclusion bodies and refolded. Further purification steps were per-
formed using a Ni‐nitrilotriacetic acid column (Qiagen) under native
conditions, followed by size exclusion chromatography using a
Superdex 200 gel filtration column (GE Healthcare Life Sciences).
EGF 6‐8 (encoding 791–900 amino acids) was codon‐optimised for
expression in E. coli (Genscript) and cloned into the plasmid pET‐45b
(+) (Novagen) using Bam HI and Xho I restriction sites to allow expres-
sion of a recombinant protein with an N‐terminal hexa‐His tag. His‐
tagged recombinant protein was purified from soluble lysate by affinity
purification on Ni‐Sepharose 6 Fast Flow resin (GE Healthcare) and
further purified by size exclusion chromatography.
EGF 5‐7 (encoding amino acids 717–860) and EGF 6‐10 (encoding
amino acids 816–987) synthetic genes (Geneart) were cloned into the
plasmid pPICZαβ (Geneart®) and transformed into Pichia pastoris. Pro-
teins were produced in a 10‐L fermentation batch and the culture
supernatant diluted with distilled water (fivefold) at pH 4.
Cation‐exchange chromatography was carried out on SP‐Sepharose.
Size‐exclusion chromatographywas utilised as an additional purification
step. Where further purification was required, reverse‐phase high‐
performance liquid chromatography (RP‐HPLC) was carried out
because these disulphide‐rich proteins are resistant to irreversible
denaturation under HPLC‐elution conditions.
None of the recombinant protein sequences were modified to
replace predicted glycosylation sites.4.2 | Immunisations
For generation of polyclonal antisera, rabbits were immunised with
200 μg of antigen in Freund's complete adjuvant and boosted at Days
28 and 56 with the same amount of antigen in Freund's incomplete
adjuvant. Serum was prepared from terminal bleeds taken at Day 70
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Rh5/CyRPA/Ripr complex, 200 μg of complexed antigens were used
as described (Wong et al., 2019). IgG was purified from serum as
described previously (Healer et al., 2013). Monoclonal antibodies were
generated as previously described (Chen et al., 2017). The animal work
was conducted at The Walter and Eliza Hall Institute of Medical
Research in accordance with WEHI animal ethics approved protocol
AEC 2017.018.4.3 | Surface plasmon resonance
Surface plasmon resonance binding assays were performed using a
BIAcore 4000 instrument, in SPR buffer as follows: 10mM HEPES,
150mM NaCl, 3.4mM EDTA, 0.005% Tween‐20, pH 7.4. Monoclonal
antibodies were immobilised as the ligand on a CM5 sensor chip sur-
face by amine coupling at densities ranging from 1,516 to 5,574 RU.
Sensorgrams were double referenced and initially fitted to a
Langmuir specific one‐site binding model and then a heterogeneous
ligand‐binding model, if appropriate, to derive on and off rates and
the dissociation constants (KD). Competitive assays were performed
by pre‐incubating the analyte with the varying concentrations (78
to 1250 ng ml−1) of the competing antibody with either CyRPA or
PfRipr at a constant 8nM prior to flowing over the ligand
immobilised surface. Kinetic parameters and competition experi-
ments were derived from three experiments performed on indepen-
dent days.4.4 | Assembly of PfRh5/CyRPA/PfRipr complex and
effect of monoclonal antibodies.
The PfRh5/CyRPA/PfRipr complex was assembled by incubating equi-
molar amounts of proteins in 20mM Tris, pH 8.5, 150mMNaCl for 1 hr
at room temperature. To test the effect of monoclonal antibodies on
complex assembly, twofold molar excesses of anti‐PfRh5, anti‐CyRPA,
or anti‐PfRipr mAbs were incubated with the respective antigens in
20mM Tris, pH 8.5, 150mM NaCl for 1 hr at room temperature. After
antigen–antibody complex formation, the remaining components of
the PfRh5/CyRPA/PfRipr complex were added to the antigen–
antibody complex for 1 hr at room temperature to enable full complex
assembly. The mixture was injected into a Superose 6 10/300 size
exclusion column in 20mM Tris, pH 8.5, 150mM NaCl. Eluted fractions
were separated by nonreducing SDS‐PAGE to determine the effect of
monoclonal antibodies on complex assembly.4.5 | Growth inhibition assays using purified IgG
Growth inhibition assays were performed as described previously
(Healer et al., 2013). Briefly, trophozoite stage parasites at 0.1%
parasitemia that were grown in a 50 μl culture at 2% haematocrit in
96 well round bottom microtitre plates (Falcon) with twofold dilutions
of each antibody. After incubation for 96 hr, each well was fixed at
room temperature for 30 min with 50 μl of 0.25% glutaraldehyde(ProSciTech) diluted in human tonicity PBS. Following centrifugation
at 1,200 rpm for 2 min, supernatants were discarded and parasites
stained with 50 μl SYBR Green (Invitrogen) diluted in PBS. The
parasitemia of each well was determined by counting 50,000 cells by
flow cytometry using a Cell Lab Quanta SC–MPL Flow Cytometer
(Beckman Coulter). Growth was expressed as a percentage of the
parasitemia obtained using a non‐immune IgG control. All samples
were tested in triplicate and standard deviation calculated.
GIA with rabbit polyclonal antibodies (results in Figure 4a) were
performed at the GIA reference centre, NIAID/NIH, using their proto-
col (Malkin et al., 2005). In brief, purified IgGs at the concentrations
described in the results section were incubated with P. falciparum‐
infected RBCs for 40 hr at 37°C. The final parasitemia was determined
by biochemical measurement of Pf lactate dehydrogenase.4.6 | Cohort study
Plasma samples were obtained from a treatment to reinfection study
of 206 children aged 5–14 performed in Madang of Papua New
Guinea (PNG). The details of this cohort have been described previ-
ously (Michon et al., 2007). Briefly, participants had oral artesunate
treatment at enrolment to clear existing infections. They were actively
monitored every 2 weeks for the symptomatic illness and parasitemia
during the 6‐month follow‐up period. Reinfection was confirmed by
using post‐polymerase chain reaction and ligase detection reaction‐
fluorescent microsphere assay and light microscopy with Giemsa‐
stained blood smears. This study was approved by the Medical
Research Advisory Committee, PNG Ministry of Health, The Walter
and Eliza Hall Institute Human Research Ethics Committee. Written
consent was obtained from parents or guardians of all participants.4.7 | Antigen conjugation and measurement of IgG
responses
Conjugation of recombinant proteins to Luminex 5.6 polystyrene
microspheres was performed as previously described (Kellar et al.,
2001). To ensure the same amount of the combined molecule on the
beads for the individual antigens and complex, the corresponding con-
centrations of each of the six conjugates used to conjugate 2.5 × 106
microspheres were as follows: PfRh5 = 4.8 μg/ml; CyRPA = 3.84 μg/
ml; PfRipr = 11.52 μg/ml; PfRh5/CyRPA = 8.64 μg/ml;
CyRPA/PfRipr = 15.36 μg/ml; PfRh5/CyRPA/PfRipr = 20.16 μg/ml.
Mouse monoclonal antibody only recognising the corresponding
PfRh5, CyRPA, and PfRipr were used to confirm the correct conjuga-
tion of antigen complex with the beads.
The multiplex antibody detection assay was performed as
described elsewhere (Franca et al., 2016; Kellar et al., 2001). Briefly,
plasma samples were diluted into 1:100 in phosphate‐buffered saline
containing 1% bovine serum albumin and 0.05% Tween (resulting
buffer was denoted as PBT). Samples were incubated with the conju-
gated beads (1:50 ratio) for 30 min under constant agitation. PE‐
conjugated donkey anti‐human IgG fragment crystallisable region (Fc)
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1 μg/mL. Beads were read on a Bio‐Plex200 reader. Results are
reported as median fluorescence intensity (MFI). A blank well without
plasma was included for determination of the true fluorescence back-
ground. As immune responses to pooled serum from immune PNG
adults are very strong, in each batch, a twofold serial dilution from
1/50 to 1/25,600 of this pool was included to generate a standard
curve to minimise the variation from different plates. The same nega-
tive control plasma used in all assays was an anonymous Melbourne
donor with no known previous exposure to malaria.4.8 | Statistical analysis
Specific standard curves from each Luminex assay plate were used for
transformation of MFIs into relative antibody units (expressed as dilu-
tion factors that range from 1.95 × 10−5 or 1/51,200 to 0.02 or 1/50)
using a five parametric logistic regression model as described previ-
ously (Franca et al., 2016).
Statistical analyses were performed using STATA version 12
(StataCorp) and R version 3.2.1 (htpp://cran.r‐project.org). The popu-
lation was categorised into terciles by antibody levels. Kaplan–Meier
curve and log‐rank test were utilised to investigate the associations
of antibody responses and time to reinfection. Cox proportional haz-
ards models were used to explore associations between antibody
responses and time to first clinical episode. Poisson regression was
performed to obtain incidence rate ratios (IRRs) for the incidence of
clinical episodes throughout the longitudinal cohort. As described else-
where, age and distance to the sea were adjusted in the above Cox
and Poisson model (Chiu et al., 2016).ACKNOWLEDGEMENTS
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